Original Article

The Effect of B-Cell Lymphoma 2 and BCL2-Associated X Polymorphisms on the Survival of Acute Lymphoblastic Leukemia Patients: Application of Frailty Survival Models

Abstract

Background: B-cell lymphoma 2 (BCL-2) and BCL-2 associated X (BAX) polymorphisms are important in the apoptosis process, response to treatment and survival in Acute Lymphoblastic Leukemia (ALL) patients. We aimed to investigate the effect of these genes with other predictors corresponding to the survival of ALL patients with an appropriate frailty survival model.

Methods: Our study was performed in 2020 on sixty-two cases of childhood aged 3-16 (year) with ALL disease who were selected by convenience sampling from the two hospitals of Tabriz, Iran. RFLPPCR method was used for genotyping the promoter region of the BAX and BCL-2 genes. We used different frailty survival models, to control heterogeneity between individuals due to unmeasured factors affecting their survival. All analyses were implemented using Stata 16.

Results:  Based on the result of log-logistic model along with frailty gamma, the proportional odds (standard error) of survival for a CC allele of BCL-2 patient compared to a AA allele patient were 6.0 (1.47); P<0.001 and for a AC of BCL-2 allele patient were 0.57 (1.23); P=0.009. Patients with AG allele of BAX had 2.05 (1.26) times greater odds of surviving than a AA allele patient (P=0.003). The odds of survival of patients with abnormal white blood cell (WBC) were 92% less than normal WBC (P<0.001).

Conclusion: With controlling unmeasured factors affecting, the BCL-2 and BAX genes promoter polymorphism are effective in the survival rates for ALL.

References
1. Buffler PA, Kwan ML, Reynolds P, Urayama KYJCi. Environmental and genetic risk factors for childhood leukemia: appraising the evidence. 2005;23(1):60-75.
2. Cook EE, MacMillan A, Gershman STJJoa, oncology ya. Cancer Among Adolescents and Young Adults in Massachusetts from 2004 to 2014. 2018;7(4):493-8.
3. Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, et al. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. 2007;92(8):1043-50.
4. Burz C, Berindan-Neagoe I, Balacescu O, Irimie AJAo. Apoptosis in cancer: key molecular signaling pathways and therapy targets. 2009;48(6):811-21.
5. Dive C, Hickman JJBjoc. Drug-target interactions: only the first step in the commitment to a programmed cell death? 1991;64(1):192-6.
6. O'connor PM, Wassermann K, Sarang M, Magrath I, Bohr VA, Kohn KWJCR. Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard. 1991;51(24):6550-7.
7. Lowe SW, Ruley HE, Jacks T, Housman DEJC. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. 1993;74(6):957-67.
8. Fisher DEJC. Apoptosis in cancer therapy: crossing the threshold. 1994;78(4):539-42.
9. White E, Chiou S-K, Rao L, Sabbatini P, Lin H-J, editors. Control of p53-dependent apoptosis by E1B, Bcl-2, and Ha-ras proteins. Cold Spring Harbor symposia on quantitative biology; 1994: Cold Spring Harbor Laboratory Press.
10. Fukunaga-Johnson N, Rayn JJ, Wicha M, Nuñez G, Clarke MFJC. Bcl-2 protects murine erythroleukemia cells from p53-dependent and-independent radiation-induced cell death. 1995;16(8):1761-7.
11. Gala JL, Vermylen C, Cornu G, Ferrant A, Michaux JL, Philippe M, et al. High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis. 1994;69(1):17-24.
12. Coustan-Smith E, Kitanaka A, Pui C-H, McNinch L, Evans WE, Raimondi SC, et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. 1996.
13. Oltval ZN, Milliman CL, Korsmeyer SJJc. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. 1993;74(4):609-19.
14. Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy GJL. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. 1995;9(7):1191-8.
15. Virgo P. Children’s Reference Ranges for FBC.
16. Moazami-Goudarzi M, Farshdousti-Hagh M, Hoseinpour-Feizi A, Talebi M, Movassaghpour-Akbari AA, Shams-Asanjan K, et al. The acute lymphoblastic leukemia prognostic scoring whether it is possible by BCL-2, BAX gene promoter genotyping. 2016;7(2):105.
17. Hougaard P. Shared frailty models. Analysis of multivariate survival data: Springer; 2000. p. 215-62.
18. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data: Springer Science & Business Media; 2006.
19. Duchateau L, Janssen P. The frailty model: Springer Science & Business Media; 2007.
20. Lancaster TJEJotES. Econometric methods for the duration of unemployment. 1979:939-56.
21. Rotolo F, Munda M, Legrand CJRpv. parfm: Parametric Frailty Models. 2012;2(2).
22. Altman D, De Stavola B, Love S, Stepniewska KJBjoc. Review of survival analyses published in cancer journals. 1995;72(2):511-8.
23. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti C, et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. 1995;71(5):1003-7.
24. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, et al. bcl-2 protein in non-small-cell lung carcinoma. 1993;329(10):690-4.
25. Kulsoom B, Shamsi TS, Afsar NA, Memon Z, Ahmed N, Hasnain SNJCm, et al. Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy? 2018;10:403.
26. Nückel H, Frey UH, Bau M, Sellmann L, Stanelle J, Dürig J, et al. Association of a novel regulatory polymorphism (− 938C> A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. 2007;109(1):290-7.
27. Thomas A, Pepper C, Hoy T, Bentley PJLr. Bcl-2 and bax expression and chlorambucil-induced apoptosis in the T-cells and leukaemic B-cells of untreated B-cell chronic lymphocytic leukaemia patients. 2000;24(10):813-21.
28. O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KRJJoco. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. 2005;23(30):7697-702.
Files
IssueVol 51 No 4 (2022) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v51i4.9251
Keywords
Acute lymphoblastic leukemia B-Cell Lymphoma 2 BCL2-Associated X Frailty models Survival
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Nikmohammadi N, Sarbakhsh P, Moazami Goudarzi M, Talebi M, Farshdousti-Hagh M, Malakouti J, Gilani N. The Effect of B-Cell Lymphoma 2 and BCL2-Associated X Polymorphisms on the Survival of Acute Lymphoblastic Leukemia Patients: Application of Frailty Survival Models. Iran J Public Health. 2022;51(4):895-903.